Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
African Journal of Urology
Published in: African Journal of Urology 1/2021

Open Access 01-12-2021 | Benign Prostatic Hypertrophy | Original Research

The effect of short-term use of finasteride versus cyproterone acetate on perioperative blood loss with monopolar transurethral resection of prostate

Authors: Shabieb A. Abdelbaki, Adel Al-Falah, Mohamed Alhefnawy, Ahmed Abozeid, Abdallah Fathi

Published in: African Journal of Urology | Issue 1/2021

Login to get access

Abstract

Background

Perioperative bleeding is the most common complication related to transurethral resection of prostate; the aim of the study was to compare the effect of pre-operative use of finasteride versus cyproterone acetate (CPA) on blood loss with monopolar TURP.

Methods

This prospective randomized controlled study was conducted on (60) patients with BPH underwent monopolar TURP between July 2019 and July 2020. Patients were distributed into three equal groups; CPA group: 20 patients received cyproterone acetate 50 mg tab BID for two weeks before TURP, finasteride group: 20 patients received single daily dose of finasteride 5 mg for two weeks before TURP, control group: 20 patients received no treatment before TURP, all patients underwent monopolar TURP, and then histopathological examination of the resected tissues was done with assessment of the microvascular density of the prostate.

Results

Our study showed that there was significant decrease in intraoperative blood loss and operative time in CPA and finasteride groups in comparison with control group (p = 0.0012) (p < 0.0001), respectively, significant decrease in post-operative Hb and HCT value in finasteride and control groups in comparison with CPA group (p < 0.01), significant increase in specimen weight in CPA group compared to other groups (p < 0.01), and there was also significant decrease in microvascular density in CPA group in comparison with other groups (p < 0.01).

Conclusion

Cyproterone acetate is more effective than finasteride in decreasing perioperative bleeding with TURP by decreasing microvascular density of the prostate.
Literature
1.
Pujari NR (2016) Transurethral resection of prostate is still the gold standard for small to moderate sized prostates. J Integr Nephrol Androl 3(2):68CrossRef
2.
Treharne C, Crowe L, Booth D, Ihara Z (2018) Economic value of the transurethral resection in saline system for treatment of benign prostatic hyperplasia in England and Wales: systematic review, meta-analysis, and cost–consequence model. Eur Urol Focus 4(2):270–279CrossRef
3.
Yang TY, Chen M, Lin WR, Li CY, Tsai WK, Chiu AW, Ko MC (2018) Preoperative treatment with 5α-reductase inhibitors and the risk of hemorrhagic events in patients undergoing transurethral resection of the prostate—A population-based cohort study. Clinics (Sao Paulo, Brazil) 73:e264
4.
Khwaja MA, Nawaz G, Muhammad S, Jamil MI, Faisal M, Akhter S (2016) The effect of two weeks preoperative finasteride therapy in reducing prostate vascularity. J Coll Phys Surg Pak 26(3):213–215
5.
Bansal A, Arora A (2017) Transurethral resection of prostate and bleeding: a prospective, randomized, double-blind placebo-controlled trial to see the efficacy of short-term use of finasteride and dutasteride on operative blood loss and prostatic microvessel density. J Endourol 31(9):910–917CrossRef
6.
Schröder FH (1993) Cyproterone acetate–-mechanism of action and clinical effectiveness in prostate cancer treatment. Cancer 72(S12):3810–3815CrossRef
7.
Bosch RJ, Griffiths DJ, Blom JH, Schroeder FH (1989) Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol 141(1):68–72CrossRef
8.
El-Gamal OM, Gameel TA, Ghoneem A, Soliman MG, Abo-El-Enen M, El-Hitham AA, El-Rasheedy M, Elbendary MA, Sabaa M (2015) Perioperative use of cyproterone acetate with transurethral resection of large prostate: preliminary results. J Endourol 29(5):569–574CrossRef
9.
El-Enen MA, Tawfik A, El-Abd AS, Ragab M, El-Abd S, Elrashidy M, El-Abd S (2016) Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial. Arab J Urol 14(1):59–65CrossRef
10.
Marshall S, Narayan P (1993) Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol 149(6):1553–1554CrossRef
11.
Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC (2000) Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 55(5):684–687CrossRef
12.
Eri LM, Tveter KJ (1993) A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 150(1):90–94CrossRef
13.
Foley SJ, Soloman, l. Z., Wedderburn, A. W., Kashif, k. M., Summerton, D., Basketter, V., & Holmes, S. A. (2000) A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 163(2):496–498CrossRef
14.
Özdal ÖL, Özden C, Benli K, Gökkaya S, Bulut S, Memiş A (2005) Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis 8(3):215–218CrossRef
15.
Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC (2005) Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 96(9):1319–1322CrossRef
16.
Perimenis P, Gyftopoulos K, Markou S, Barbalias G (2002) Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. Urology 59(3):373–377CrossRef
17.
Crea G, Sanfilippo G, Anastasi G, Magno C, Vizzini C, Inferrera A (2005) Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int 74(1):51–53CrossRef
18.
Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC (2002) Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol 168(5):2024–2026CrossRef
19.
Memis A, Ozden C, Ozdal OL, Guzel O, Han O, Seckin S (2008) Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia. Urol Int 80(2):177–180CrossRef
20.
Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G, Fracchia JA (2002) Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 167(4):1731–1733CrossRef
21.
Kaplan SA (2019) Re: Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density. J Urol 201(2):202–202CrossRef
22.
Canda AE, Mungan MU, Yilmaz O, Yorukoglu K, Tuzel E, Kirkali Z (2006) Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. Int Urol Nephrol 38(2):275–280CrossRef
23.
Zhu YP, Dai B, Zhang HL, Shi GH, Ye DW (2015) Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urol 15(1):1–11CrossRef
24.
Fonseca RC, Gomes CM, Meireles EB, Freire GC, Srougi M (2008) Prostate specific antigen levels following transurethral resection of the prostate. Int Braz J Urol 34(1):41–48CrossRef
Metadata
Title
The effect of short-term use of finasteride versus cyproterone acetate on perioperative blood loss with monopolar transurethral resection of prostate
Authors
Shabieb A. Abdelbaki
Adel Al-Falah
Mohamed Alhefnawy
Ahmed Abozeid
Abdallah Fathi
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
African Journal of Urology / Issue 1/2021
Print ISSN: 1110-5704
Electronic ISSN: 1961-9987
DOI
https://doi.org/10.1186/s12301-021-00211-4

Other articles of this Issue 1/2021

African Journal of Urology 1/2021 Go to the issue

Original Research

Pathological correlation between prostate biopsies and the radical prostatectomy, about 30 cases

Original Research

Evaluation of Juniperus communis L. seed extract on benign prostatic hyperplasia induced in male Wistar rats

Original Research

Safety and efficacy of mini-percutaneous nephrolithotomy as daycare procedure: a prospective observational study

Original Research

Two-year follow-up after holmium laser enucleation of the prostate and bipolar transurethral resection of the prostate: a prospective randomized study

Original Research

Relationship between serum prostate-specific antigen and transrectal prostate sonographic findings in asymptomatic Ugandan males

Original Research

Is the simple webbed penis a contraindication to circumcision?